127 related articles for article (PubMed ID: 33147051)
1. Expression of COX-2, p16, and Ki67 in the range from normal breast tissue to breast cancer.
Feriancová M; Walter I; Singer CF; Gazdarica J; Pohlodek K
Neoplasma; 2021 Mar; 68(2):342-351. PubMed ID: 33147051
[TBL] [Abstract][Full Text] [Related]
2. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
[TBL] [Abstract][Full Text] [Related]
3. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
4. Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast.
Perez AA; Balabram D; Rocha RM; da Silva Souza Á; Gobbi H
J Histochem Cytochem; 2015 Jun; 63(6):408-16. PubMed ID: 25711229
[TBL] [Abstract][Full Text] [Related]
5. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
[TBL] [Abstract][Full Text] [Related]
6. p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia.
Radisky DC; Santisteban M; Berman HK; Gauthier ML; Frost MH; Reynolds CA; Vierkant RA; Pankratz VS; Visscher DW; Tlsty TD; Hartmann LC
Cancer Prev Res (Phila); 2011 Dec; 4(12):1953-60. PubMed ID: 21920875
[TBL] [Abstract][Full Text] [Related]
7. Significance of flat epithelial atypia on mammotome core needle biopsy: Should it be excised?
Kunju LP; Kleer CG
Hum Pathol; 2007 Jan; 38(1):35-41. PubMed ID: 17095049
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of p16 and p53 characterizes aggressive subtypes of ductal intraepithelial neoplasia.
Bechert C; Kim JY; Tramm T; Tavassoli FA
Virchows Arch; 2016 Dec; 469(6):659-667. PubMed ID: 27664050
[TBL] [Abstract][Full Text] [Related]
9. Flat epithelial atypia with and without atypical ductal hyperplasia: to re-excise or not. Results of a 5-year prospective study.
Uzoaru I; Morgan BR; Liu ZG; Bellafiore FJ; Gaudier FS; Lo JV; Pakzad K
Virchows Arch; 2012 Oct; 461(4):419-23. PubMed ID: 22961104
[TBL] [Abstract][Full Text] [Related]
10. Promoter CpG island hypermethylation during breast cancer progression.
Park SY; Kwon HJ; Lee HE; Ryu HS; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
Virchows Arch; 2011 Jan; 458(1):73-84. PubMed ID: 21120523
[TBL] [Abstract][Full Text] [Related]
11. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
12. bcl-2 expression in the spectrum of preinvasive breast lesions.
Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ
Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957
[TBL] [Abstract][Full Text] [Related]
13. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma.
Qi L; Bart J; Tan LP; Platteel I; Sluis Tv; Huitema S; Harms G; Fu L; Hollema H; Berg Av
BMC Cancer; 2009 May; 9():163. PubMed ID: 19473551
[TBL] [Abstract][Full Text] [Related]
14. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ.
Davis JE; Nemesure B; Mehmood S; Nayi V; Burke S; Brzostek SR; Singh M
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):20-5. PubMed ID: 26317313
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Sasano H
Jpn J Cancer Res; 2000 Nov; 91(11):1169-76. PubMed ID: 11092983
[TBL] [Abstract][Full Text] [Related]
16. p16(INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma.
Di Vinci A; Perdelli L; Banelli B; Salvi S; Casciano I; Gelvi I; Allemanni G; Margallo E; Gatteschi B; Romani M
Int J Cancer; 2005 Apr; 114(3):414-21. PubMed ID: 15578730
[TBL] [Abstract][Full Text] [Related]
17. Expression of cyclins in ductal hyperplasia, atypical ductal hyperplasia and ductal carcinoma in situ of the breast.
Kim HJ; Jung WH; Kim DY; Lee HD
Yonsei Med J; 2000 Jun; 41(3):345-53. PubMed ID: 10957889
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical study of matrix metalloproteinase 9 and tissue inhibitor of matrix metalloproteinase 1 in benign and malignant breast tissue--strong expression in intraductal carcinomas of the breast.
Rahko E; Kauppila S; Pääkkö P; Blanco G; Apaja-Sarkkinen M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Jukkola A
Tumour Biol; 2009; 30(5-6):257-64. PubMed ID: 19887890
[TBL] [Abstract][Full Text] [Related]
19. Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors.
Sugianto J; Sarode V; Peng Y
Hum Pathol; 2014 Apr; 45(4):802-9. PubMed ID: 24560018
[TBL] [Abstract][Full Text] [Related]
20. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
